Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
Ashley M HopkinsGanessan KichenadasseElizabeth Garrett-MayerChristos S KarapetisAndrew RowlandMichael J SorichPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
A prognostic tool was developed and validated to identify patient groups with distinctly different survival following atezolizumab initiation for advanced NSCLC.